Beurs gesloten -
Andere beurzen
|
Variatie 5 dagen | Verschil t.o.v. 1 jan (%) | ||
1,75 USD | +2,94% | +0,57% | -25,53% |
28/03 | XERIS BIOPHARMA HOLDINGS, INC. : Oppenheimer verhoogt advies van Neutraal naar Kopen | ZM |
06/03 | Transcript : Xeris Biopharma Holdings, Inc., Q4 2023 Earnings Call, Mar 06, 2024 |
Omzet 2024 * | 184 mln. 172 mln. | Omzet 2025 * | 219 mln. 205 mln. | Marktkapitalisatie | 259 mln. 243 mln. |
---|---|---|---|---|---|
Nettowinst (verlies) 2024 * | -55 mln. -51,44 mln. | Nettowinst (verlies) 2025 * | -27 mln. -25,25 mln. | EV/omzet 2024 * | 1,41 x |
Nettoliquiditeiten 2024 * | - 0 | Nettoliquiditeiten 2025 * | - 0 | EV/omzet 2025 * | 1,18 x |
K/w-verhouding 2024 * |
-4,55
x | K/w-verhouding 2025 * |
-9,55
x | Werknemers | 377 |
Dividendrendement 2024 * |
-
| Dividendrendement 2025 * |
-
| Vrij verhandelbaar | 96,26% |
Recentste transcriptie over Xeris Biopharma Holdings, Inc.
1 dag | +2,94% | ||
1 week | +0,57% | ||
Lopende maand | -20,81% | ||
1 maand | -14,22% | ||
3 maanden | -29,72% | ||
6 maanden | +8,70% | ||
Lopend jaar | -25,53% |
Managers | Titel | Leeftijd | Van |
---|---|---|---|
Founder | 60 | 01-01-05 | |
Paul Edick
CEO | Chief Executive Officer | 67 | 05-10-21 |
Steven Pieper
DFI | Director of Finance/CFO | 47 | 01-01-21 |
Besturend | Titel | Leeftijd | Van |
---|---|---|---|
John Johnson
BRD | Director/Board Member | 66 | 05-10-21 |
Jeffrey Sherman
BRD | Director/Board Member | 69 | 05-10-21 |
Marla Persky
BRD | Director/Board Member | 68 | 05-10-21 |
Naam | Gewicht | Volume | Vaira. 1 jan. | belegger rating |
---|---|---|---|---|
0.00% | 9 M€ | +6,26% | - | |
0.00% | 147 M€ | +4,88% | - |
Datum | Koers | Variatie | Volume |
---|---|---|---|
26-04-24 | 1,75 | +2,94% | 870 181 |
25-04-24 | 1,7 | -3,41% | 894 039 |
24-04-24 | 1,76 | -1,12% | 712 941 |
23-04-24 | 1,78 | 0,00% | 1 345 307 |
22-04-24 | 1,78 | +2,30% | 1 319 079 |
uitgestelde koers Nasdaq, 26 april 2024 om 22:00 uur
Meer koersenHerzieningen van WPA
Vaira. 1 jan. | Kapi. | |
---|---|---|
-25,53% | 259 mln. | |
+25,83% | 661 mld. | |
+27,00% | 566 mld. | |
-6,76% | 352 mld. | |
+20,34% | 332 mld. | |
+3,00% | 283 mld. | |
+13,09% | 231 mld. | |
+5,46% | 200 mld. | |
-9,61% | 195 mld. | |
-6,26% | 145 mld. |